J&J's Janssen Gets Europe OK for Twice-Yearly Schizophrenia Treatment
November 23 2021 - 7:18AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Tuesday said the European Commission approved the company's Byannli
six-month maintenance treatment for schizophrenia in adults.
The drugmaker said the approval, which covers patients who are
clinically stable on monthly or three-month doses, makes Byannli
the first twice-yearly treatment of schizophrenia in adults in
Europe.
The U.S. Food and Drug Administration in September approved a
six-month version of the antipsychotic, marketed in the U.S. as
Invega.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2021 07:03 ET (12:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024